These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19670217)

  • 1. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
    Marchiò C; Lambros MB; Gugliotta P; Di Cantogno LV; Botta C; Pasini B; Tan DS; Mackay A; Fenwick K; Tamber N; Bussolati G; Ashworth A; Reis-Filho JS; Sapino A
    J Pathol; 2009 Sep; 219(1):16-24. PubMed ID: 19670217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
    Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
    Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort.
    Koudelakova V; Trojanec R; Vrbkova J; Donevska S; Bouchalova K; Kolar Z; Varanasi L; Hajduch M
    Genes Chromosomes Cancer; 2016 May; 55(5):409-17. PubMed ID: 26847577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.
    Holzschuh MA; Czyz Z; Hauke S; Inwald EC; Polzer B; Brockhoff G
    Histopathology; 2017 Oct; 71(4):610-625. PubMed ID: 28502100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V; Voutsadakis IA
    Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
    Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
    Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.
    Troxell ML; Bangs CD; Lawce HJ; Galperin IB; Baiyee D; West RB; Olson SB; Cherry AM
    Am J Clin Pathol; 2006 Nov; 126(5):709-16. PubMed ID: 17050068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
    Viale G
    J Pathol; 2009 Sep; 219(1):1-2. PubMed ID: 19670216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
    Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
    BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
    Zare S; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HER2 status in breast cancer of Chinese women: a study of 1170 cases using fluorescence in-situ hybridization].
    Zeng X; Liang ZY; Wu SF; Gao J; Zhou WX; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):594-8. PubMed ID: 19094582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
    Katayama A; Starczynski J; Toss MS; Shaaban AM; Provenzano E; Quinn CM; Callagy G; Purdie CA; Millican-Slater R; Purnell D; Chagla L; Oyama T; Pinder SE; Chan S; Ellis I; Lee AHS; Rakha EA
    Histopathology; 2022 Oct; 81(4):511-519. PubMed ID: 35879836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
    Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
    Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.